- Home
- VECO vs KNSA Comparison
VECO vs KNSA Comparison
Compare VECO & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VECO
- KNSA
- Stock Information
- Founded
- VECO 1945
- KNSA 2015
- Country
- VECO United States
- KNSA United Kingdom
- Employees
- VECO N/A
- KNSA N/A
- Industry
- VECO Industrial Machinery/Components
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- VECO Technology
- KNSA Health Care
- Exchange
- VECO Nasdaq
- KNSA Nasdaq
- Market Cap
- VECO 1.5B
- KNSA 1.4B
- IPO Year
- VECO 1994
- KNSA 2018
- Fundamental
- Price
- VECO $24.73
- KNSA $20.02
- Analyst Decision
- VECO Buy
- KNSA Strong Buy
- Analyst Count
- VECO 7
- KNSA 5
- Target Price
- VECO $32.43
- KNSA $36.60
- AVG Volume (30 Days)
- VECO 796.0K
- KNSA 567.6K
- Earning Date
- VECO 02-12-2025
- KNSA 02-25-2025
- Dividend Yield
- VECO N/A
- KNSA N/A
- EPS Growth
- VECO N/A
- KNSA N/A
- EPS
- VECO 1.23
- KNSA N/A
- Revenue
- VECO $717,301,000.00
- KNSA $384,098,000.00
- Revenue This Year
- VECO N/A
- KNSA $60.10
- Revenue Next Year
- VECO $8.64
- KNSA $34.22
- P/E Ratio
- VECO $20.10
- KNSA N/A
- Revenue Growth
- VECO 7.63
- KNSA 54.41
- 52 Week Low
- VECO $23.00
- KNSA $16.56
- 52 Week High
- VECO $49.25
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- VECO 45.05
- KNSA 53.15
- Support Level
- VECO $23.00
- KNSA $19.31
- Resistance Level
- VECO $26.11
- KNSA $20.20
- Average True Range (ATR)
- VECO 0.83
- KNSA 0.80
- MACD
- VECO 0.13
- KNSA 0.06
- Stochastic Oscillator
- VECO 55.63
- KNSA 72.80
About VECO Veeco Instruments Inc.
Veeco Instruments Inc is a United States-based company that is principally engaged in designing, developing, and manufacturing thin-film process equipment, which is mainly used to produce electronic devices. The company's product categories by market consist of lighting, display, and power electronics; advanced packaging; MEMS and RF; scientific and industrial; and data storage. The lighting, display, and power electronics market accounts for over half of the total revenue. The company offers products and services in the United States; China; Europe, the Middle East, and Africa, or EMEA; and the rest of the world, with overseas markets contributing the majority of total revenue.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.